
    
      All eligible patients will receive combined modality treatment initially. Systemic treatment
      will begin 4-6 weeks after completion of the Combined Modality portion and will complete 4
      cycles of a 4 week regimen. Patients with no evidence of disease following systemic therapy
      may continue single agent bevacizumab for up to one year. After all treatment is completed,
      patients will be re-evaluated with imaging to establish a new baseline. Patients will be
      re-evaluated thereafter for up to a total of 5 years.

      Combined Modality Treatment:

        -  bevacizumab 5mg/kg IV infusion days 1, 15, and 29

        -  fluorouracil 225mg/m2 IV continuous infusion days 1-42

        -  radiation 1.8 Gy/day or 28 fractions weeks 1-6

      Systemic Treatment:

        -  5-fluorouracil 400 mg/m2 bolus

        -  5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15

        -  leucovorin 350 mg prior to FU on days 1 and 15

        -  oxaliplatin 85 mg/m2 days 1 and 15

        -  bevacizumab 5 mg/kg days 1 and 15
    
  